Table 2 Correlation of HHLA2 expression with clinicopathological parameters in ovarian cancer
From: HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer
Variable | Number of patients | HHLA2 Expression | ||
|---|---|---|---|---|
+ | − | P Value | ||
Age | ||||
≥ 50 | 42 | 7 | 35 | 1.000 |
< 50 | 22 | 4 | 18 | |
Histological type | ||||
Serous adenocarcinoma | 50 | 8 | 42 | 0.940 |
Others | 14 | 3 | 11 | |
Differentiation | ||||
Poor | 26 | 2 | 24 | 0.027 |
Moderate | 25 | 4 | 21 | |
Well | 13 | 5 | 8 | |
FIGO Stage | ||||
I | 9 | 3 | 6 | 0.160 |
II | 6 | 1 | 5 | |
III | 36 | 6 | 30 | |
IV | 13 | 1 | 12 | |
Metastasis | ||||
+ | 51 | 8 | 43 | 0.532 |
− | 13 | 3 | 10 | |
Ascites | ||||
+ | 11 | 1 | 10 | 0.732 |
− | 53 | 10 | 43 | |
Vessel Invasion | ||||
+ | 3 | 0 | 3 | 1.000 |
− | 61 | 11 | 50 | |
Lymph Node | ||||
+ | 8 | 2 | 6 | 0.900 |
− | 56 | 9 | 47 | |
Platinum Sensitivity | ||||
Platinum sensitive | 50 | 8 | 42 | 0.940 |
Platinum resistance | 14 | 3 | 11 | |
Relapse | ||||
+ | 27 | 4 | 23 | 0.925 |
− | 37 | 7 | 30 | |
Serum CA125 Before Surgery | ||||
< 35 | 4 | 1 | 3 | 0.539 |
≥ 35 | 60 | 10 | 50 | |
CA125 | ||||
+ | 37 | 5 | 32 | 0.148 |
− | 5 | 2 | 5 | |
Unknown | 19 | 4 | 16 | |
ER | ||||
+ | 39 | 8 | 34 | 1.000 |
− | 17 | 3 | 15 | |
Unknown | 4 | 0 | 4 | |
PR | ||||
+ | 33 | 6 | 29 | 1.000 |
− | 23 | 5 | 20 | |
Unknown | 4 | 0 | 4 | |